Dose Efficacy in Adhesive Capsulitis

NCT ID: NCT06848374

Last Updated: 2025-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-20

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if the treatment of adhesive capsulitis with 40 mg of methylprednisolone in combination with a hydrodilatation is comparable to 80 mg of methylprednisolone for pain reduction, improving shoulder mobility, and reducing side effects.

Researchers will enroll 40 people in this study which is taking place solely at the Toronto Rehabilitation Institute, University Avenue. This study should take approximately 12 months to complete and the results should be known in about 15 to 18 months. During this study, patients will receive an ultrasound guided shoulder hydrodilatation combined with corticosteroid after "randomized" into one of the groups (40 mg vs 80 mg). This is a double blind study as both patients and physicians would not know the group patient was randomized to.

Pain scores, Range of Motion and few other questionnaires wold be completed to track the response to the interventions at baseline prior to injection, four weeks after the procedure and 3 months after the procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adhesive Capsulitis of the Shoulder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

40mg methylprednisolone dose

Group Type ACTIVE_COMPARATOR

40 mg Methylprednisolone

Intervention Type DRUG

Ultrasound guided injection of 40mg methylprednisolone injection

Group B

80mg methylprednisolone dose

Group Type ACTIVE_COMPARATOR

80 mg Methylprednisolone

Intervention Type DRUG

Ultrasound guided injection of 40mg methylprednisolone injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

40 mg Methylprednisolone

Ultrasound guided injection of 40mg methylprednisolone injection

Intervention Type DRUG

80 mg Methylprednisolone

Ultrasound guided injection of 40mg methylprednisolone injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years of age
* Diagnostic of adhesive capsulitis of the shoulder

Exclusion Criteria

* Injection received in the affected shoulder \< 3 months ago (any kind)
* History of previous surgery in the affected shoulder
* Glenohumeral osteoarthritis more than mild on the xray
* Pregnancy
* Blood thinner (other than Aspirin 80 mg) or bleeding disorder
* Active infection (requiring antibiotic)
* Allergy to steroid or lidocaine
* Cognitive impairment
* Active litigation
* Inflammatory connective tissue disorder
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Health Network, Toronto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nimish Mittal

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toronto Rehabilitation Institution

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nimish Mittal

Role: CONTACT

416-597-3422

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nimish Mitta;

Role: primary

416-597-3422

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

24-5123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.